A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

NCT06856200 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Advanced HR - Positive, HER2 - Negative Breast Cancer
Resistant to (Neo)Adjuvant Endocrine Therapy

Interventions

DRUG: Sirolimus (albumin - bound)
DRUG: Palbociclib
DRUG: Fulvestrant

Sponsor

Fudan University